Abstract: The present invention relates to a process for the isolation of bioactive components from spent turmeric (Curcuma longa) and compositions comprising said bioactive components. Further, the present invention also elucidates the potent anti-inflammatory activity of said bioactive compositions and therapeutic applications thereof in rheumatoid arthritis.

Abstract: Disclosed are the compositions comprising bioactive components Oroxylin A-7-glucuronide, Baicalein-7-glucuronide and Chrysin-7-glucuronide, isolated from the bark of Oroxylum indicum, and the process of isolating the said bioactive components.

Abstract: Disclosed are compositions enriched with thymohydroquinone, further comprising of thymoquinone, hederagenin and/or ?-hederin formulated by blending the active molecules isolated from the seeds of Nigella sativa. Also disclosed are novel processes for the isolation of bioactive components thymohydroquinone, thymoquinone from the seeds of Nigella sativa. A process for the isolation ?-hederin and hederagenin from the spent material of Nigella sativa is also disclosed herein.

Abstract: The present invention relates to a process for the isolation of bioactive components from spent turmeric (Curcuma longa) and compositions comprising said bioactive components. Further, the present invention also elucidates the potent anti-inflammatory activity of said bioactive compositions and therapeutic applications thereof in rheumatoid arthritis.

Abstract: Disclosed are the compositions comprising bioactive components Oroxylin A, Baicalein, Chrysin, and their glucuronides Oroxylin A-7-glucuronide, Baicalein-7-glucuronide and Chrysin-7-glucuronide, isolated from the bark of Oroxylum indicum, and the process of isolating the said bioactives.

Abstract: Disclosed is a novel process for the isolation of bioactive compounds from Terminalia arjuna. More specifically, the invention discloses a process for isolation and enrichment of bioactive compounds Arjunic acid, Arjunolic acid, Arjungenin, Arjunetin, Arjunoglucoside-I, Arjunoglucoside-II, and Catechin from the bark of Terminalia arjuna. The invention also discloses a composition standardized to contain 3% arjunoglucosides isolated from the bark of Terminalia arjuna.

Abstract: Disclosed are compositions enriched with thymohydroquinone, further comprising of thymoquinone, hederagenin and/or ?-hederin formulated by blending the active molecules isolated from the seeds of Nigella sativa. Also disclosed are novel processes for the isolation of bioactive components thymohydroquinone, thymoquinone from the seeds of Nigella sativa. A process for the isolation ?-hederin and hederagenin from the spent material of Nigella sativa is also disclosed herein.

Abstract: Disclosed are methods of managing hypercholesterolemia using a composition of matter comprising the ethyl acetate fraction of the extract of Cyperus rotundus rhizomes standardized to contain 5% of total stilbenes.

Abstract: Disclosed is a novel process for the isolation of bioactive compounds from Terminalia arjuna. More specifically, the invention discloses a process for isolation and enrichment of bioactive compounds Arjunic acid, Arjunolic acid, Arjungenin, Arjunetin, Arjunoglucoside-I, Arjunoglucoside-II, and Catechin from the bark of Terminalia arjuna. The invention also discloses a composition standardized to contain 3% arjunoglucosides isolated from the bark of Terminalia arjuna.

Abstract: Disclosed are the compositions comprising bioactive components Oroxylin A, Baicalein, Chrysin, and their glucuronides Oroxylin A-7-glucuronide, Baicalein-7-glucuronide and Chrysin-7-glucuronide, isolated from the bark of Oroxylum indicum, and the process of isolating the said bioactives.

Abstract: Disclosed are methods of managing obesity and hypercholesterolemia using a composition of matter comprising the ethyl acetate fraction of the extract of Cyperus rotundus rhizomes standardized to contain 5% of total stilbenes.

Abstract: Disclosed are methods of managing hypercholesterolemia using a composition of matter comprising the ethyl acetate fraction of the extract of Cyperus rotundus rhizomes standardized to contain 5% of total stilbenes.

Abstract: Disclosed is a composition comprising scirpusin A and scirpusin B and anti-obesity potential thereof. Also disclosed are methods of inhibiting adipogenesis using a composition comprising scirpusin A and scirpusin B. The present invention also disclosed methods of therapeutically managing obesity in mammals using a composition comprising scirpusin A and scirpusin B. Still further, the present invention also relates to a method of obtaining compositions comprising A. scirpusin A and scirpusin B and B. piceatannol and its dimers scirpusin A and scirpusin B through bioactivity guided fractionation of the rhizomes of Cyperus rotundus.

Abstract: The present invention relates to preservation of cosmetic formulations. More specifically, the present invention relates to a preservative composition for cosmetic formulations comprising thymol, monolaurin and magnolol obtained from supercritical fluid extracts of Magnolia officinalis.

Abstract: Disclosed are methods of managing obesity and hypercholesterolemia using a composition of matter comprising the ethyl acetate fraction of the extract of Cyperus rotundus rhizomes standardized to contain 5% of total stiibenes.

Abstract: Disclosed are the uses of triterpene glycosides as non-toxic natural solubilizing agents for bioactive compounds and/or metabolites thereof. Triterpene glycosides are also shown to solubilize insoluble natural extracts. Also disclosed are exemplary methods and compositions incorporating the uses of triterpene glycosides as non-toxic natural solubilizing agents.

Abstract: The present invention relates to preservation of cosmetic formulations. More specifically, the present invention relates to a preservative composition for cosmetic formulations comprising thymol, monolaurin and magnolol obtained from supercritical fluid extracts of Magnolia officinalis.

Abstract: The present invention relates to preservation of cosmetic formulations. More specifically, the present invention relates to a preservative composition for cosmetic formulations comprising thymol, monolaurin and magnolol obtained from supercritical fluid extracts of Magnolia officinalis.

Abstract: Disclosed are novel protective compositions for dermal papilla cells. In an embodiment the protective compositions of the present invention comprise 0.25% w/w or above of compositions comprising at least 10% w/w and above of 1-O-galloyl-?-D-glucose (?-glucogallin). In an embodiment, the said protective composition additionally comprises 50% to greater than 50% gallates including mucic acid 1,4-lactone 5-O-gallate, mucic acid 2-O-gallate, mucic acid 6-Methyl ester 2-O-gallate, mucic acid 1-Methyl ester 2-O-gallate and ellagic acid. In another embodiment the invention also encompasses synergistic protective compositions comprising the said protective compositions and 0.5% concentrate of liquid endosperm of Cocos nucifera, for dermal papilla directed towards helping the dermal papilla cells to form sufficient numbers and to retain a healthy morphology conducive for hair growth.

Abstract: The present invention relates to preservation of cosmetic formulations. More specifically, the present invention relates to a preservative composition for cosmetic formulations comprising thymol, monolaurin and magnolol obtained from supercritical fluid extracts of Magnolia officinalis.